Core Viewpoint - Hofseth BioCare ASA ("HBC") is conducting a private placement of new shares to raise capital for growth, balance sheet strengthening, and general corporate purposes, with a total size of approximately NOK 158 million from the issuance of 87,811,110 shares at NOK 1.80 each [2][3][4]. Group 1: Private Placement Details - The private placement consists of two tranches: Tranche 1 will raise NOK 106.5 million, while Tranche 2 will raise NOK 28.67 million, with the total expected proceeds being between NOK 155 million and NOK 181 million [2][4]. - The share capital increase will be executed through the issuance of 59,144,444 shares with a par value of NOK 0.01, and the first trading day for Tranche 1 shares is expected on or about 29 October 2025 [4][6]. - The completion of the private placement is contingent upon the registration of the share capital increase and the satisfaction of specific conditions related to the divestment of shares in AecorBio [5]. Group 2: Investor Participation - Major investors include Guy Urquhart, who subscribed for 55,444,444 shares for approximately NOK 100 million, and Hofseth International AS, which subscribed for 28,666,666 shares for about NOK 52 million [7]. - Shareholders representing 68.2% of the outstanding shares have committed to vote in favor of the share capital increase for Tranche 2 [6]. Group 3: Subsequent Offering - A subsequent offering of up to 16,666,666 new shares may be conducted, aimed at existing shareholders who did not participate in the private placement, potentially raising an additional NOK 30 million [9]. - The subsequent offering is subject to corporate approvals and market conditions, and any remaining shares may be allocated to strategic investors at the Board's discretion [9]. Group 4: Compliance and Structure - The Board of Directors has ensured that the private placement complies with Norwegian laws regarding equal treatment of shareholders and has structured the transaction to minimize completion risks compared to a rights issue [8]. - The proposed private placement is considered to be in the common interest of the company and its shareholders, despite deviations from shareholders' preferential rights [8].

Core Viewpoint - Vivoryon Therapeutics N.V. has successfully completed a private placement, raising EUR 5.1 million to support the development of its lead candidate, varoglutamstat, for chronic kidney disease [2][3][6]. Financial Summary - The private placement involved the issuance of 3,380,500 new ordinary shares at an offering price of EUR 1.50 per share, resulting in gross proceeds of EUR 5.1 million [4]. - The new shares represent 12.9% of Vivoryon's existing issued share capital, increasing the total number of shares outstanding to 29,614,337 and the share capital to EUR 296,143.37 [4][8]. Use of Proceeds - The funds raised will be utilized for the ongoing clinical development of varoglutamstat, securing a strategic partnership, and potentially additional funding for a planned Phase 2 study in diabetic kidney disease [6][8]. - The company anticipates that the existing cash, including the proceeds from this placement, will be sufficient to fund operations into Q3 2026 [7][8]. Market Position and Strategy - Vivoryon is focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly targeting kidney diseases [3][9]. - The successful financing reflects investor confidence in the company's strategy and its program for varoglutamstat [6].

Core Points - TrustBIX Inc. has announced an extension for its non-brokered private placement, allowing it to complete the offering by September 2, 2025, with a maximum of 10,000,000 units priced at $0.04 each, aiming for gross proceeds of up to $400,000 [1][2]. Group 1: Private Placement Details - Each unit consists of one common share and one warrant, with the warrant allowing the purchase of an additional common share at $0.08 for two years [3]. - If the closing price of the common shares exceeds $0.12 for 20 consecutive trading days, TrustBIX can accelerate the expiry date of the warrants [3]. - The proceeds from the private placement will be utilized for general working capital, including inventory acquisition to support ongoing operations [4]. Group 2: Regulatory and Compliance Information - The common shares will be sold under prospectus exemptions available under National Instrument 45-106, targeting accredited investors, employees, executives, directors, consultants, and existing security holders [5]. - The securities issued will be subject to a statutory hold period of four months and one day following the closing of the private placement [4]. Group 3: Company Overview - TrustBIX is an agricultural technology company focused on providing Gate to Plate® solutions aimed at enhancing trust, reducing waste, and promoting sustainable practices within the agri-food sector [6].

Core Points - Kaldvík AS successfully completed a private placement raising approximately NOK 532 million (around EUR 46.2 million) [1] - The private placement consists of two tranches: Tranche 1 with 5,976,172 shares and Tranche 2 with 32,034,878 shares, pending approval from an extraordinary general meeting [2] - Austur Holding AS lent 1,724,097 existing shares to facilitate the settlement of the private placement [3] - Close associates of primary insiders subscribed for significant shares: Austur Holding AS subscribed for 27,045,027 shares, while AR-Invest AS subscribed for 32,910 shares [5]

Core Points - Kaldvík AS successfully completed a private placement raising approximately NOK 532 million (around EUR 46.2 million) [1] - The private placement consists of two tranches: Tranche 1 with 5,976,172 shares and Tranche 2 with 32,034,878 shares, pending approval from an extraordinary general meeting [2] - Austur Holding AS lent 1,724,097 existing shares to facilitate the settlement of the private placement [3] Transactions by Close Associates - Austur Holding AS subscribed for 27,045,027 new shares in the private placement and lent shares to DNB Carnegie for settlement [5] - AR-Invest AS, associated with primary insider Asle Rønning, subscribed for 32,910 new shares in the private placement [5]